Bausch Health Companies Inc. (BHC)
| Market Cap | 2.12B |
| Revenue (ttm) | 10.27B |
| Net Income (ttm) | 157.00M |
| Shares Out | 373.46M |
| EPS (ttm) | 0.42 |
| PE Ratio | 13.50 |
| Forward PE | 1.30 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,443,525 |
| Open | 5.62 |
| Previous Close | 5.58 |
| Day's Range | 5.60 - 5.79 |
| 52-Week Range | 4.41 - 8.69 |
| Beta | 0.40 |
| Analysts | Hold |
| Price Target | 8.00 (+41.09%) |
| Earnings Date | Apr 29, 2026 |
About BHC
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for BHC stock is "Hold." The 12-month stock price target is $8.0, which is an increase of 41.09% from the latest price.
News
Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Ophthalmo...
Bausch Health's Dermatology Business, Ortho Dermatologics, Announces the Launch of Biafine®, an Iconic French Skincare Product, Through Convenient Online Ordering
The skin recovery emulsion for dry, sensitive, or stressed skin is now available through select online channels LAVAL, QC, April 14, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BH...
Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced Update
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. ...
Bausch + Lomb Launches Preloaded enVista Envy™ Full Range of Vision Intraocular Lenses in Europe
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced European comme...
Bausch Health to Announce First Quarter 2026 Results on April 29, 2026
LAVAL, QC, March 31, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter 2026 financial results after market close on Wednesday, April 29, 2026. Bausch Hea...
Bausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program
Bausch Health is offering scholarships to six students impacted by dermatologic conditions, with applications open through June 2026 LAVAL, QC, March 26, 2026 /PRNewswire/ -- Bausch Health Companies I...
Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada
LAVAL, QC, Feb. 23, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in medical aesthetics, today...
Bausch Health's OraPharma Celebrates 25 Years of ARESTIN® (minocycline HCl) Microspheres
The only FDA‑approved locally applied antibiotic used with scaling and root planing (SRP) marks a quarter‑century of clinical use LAVAL, QC, Feb. 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. ...
Bausch Health Companies Earnings Call Transcript: Q4 2025
Delivered eleventh straight quarter of revenue and adjusted EBITDA growth, with 2025 results exceeding guidance and strong performance across all segments. 2026 guidance calls for continued growth, though 2027 EBITDA is expected to dip due to pricing and exclusivity changes.
BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS
Fourth Quarter Consolidated Revenues of $2.80 billion, up 9% on a Reported basis and up 6% on an Organic (non-GAAP) 1 basis over the prior year period Full-Year Consolidated Revenues of $10.27 billio...
Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference
LAVAL, QC, Feb. 17, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Executive Vice President and CFO Jean-Jacques (JJ) Charhon, along with other management t...
Bausch Health Announces 2026 Gastrointestinal Health Scholars Program
Bausch Health to Provide Scholarships to 10 Students Living with GI Diseases LAVAL, QC, Feb. 11, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology (GI) b...
Bausch Health's brain dysfunction treatment fails late-stage trial
Bausch Health said on Friday its treatment to prevent brain dysfunction in patients with liver cirrhosis did not meet the main goal of a late-stage trial.
Bausch Health Provides Update on RED-C Phase 3 Clinical Trials
LAVAL, QC, Jan. 23, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced the results of the global Phase 3 RED-C clinical program evaluating amorphous-rifaximin solid...
Bausch Health to Announce Fourth Quarter and Full Year 2025 Results on February 18, 2026
LAVAL, QC, Jan. 21, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2025 financial results after market close on Wednesday, February 18,...
Bausch Health Companies Transcript: 44th Annual J.P. Morgan Healthcare Conference
Management emphasized profitable growth, capital structure improvement, and innovation across four business segments. Key growth drivers include Salix, Solta, and international markets, with major pipeline readouts (RED-C, larsucosterol) expected soon.
Bausch Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
LAVAL, QC, Jan. 5, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that Thomas J. Appio, Chief Executive Officer, will participate at the 44th Annual J.P.
Bausch Health Announces Final Results and Expiration of Exchange Offers
LAVAL, QC / ACCESS Newswire / December 23, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company") and its subsidiary 1261229 B.C. Ltd. (the "Issuer" and, together with the Company, th...
Bausch Health Announces Early Exchange Offer Results for Exchange Offers
LAVAL, QC / ACCESS Newswire / December 8, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company") announced today the results to date of its previously announced offers to exchange the...
Bausch Health Companies Transcript: Evercore ISI 8th Annual HealthCONx Conference
Management outlined a strategy focused on growth in GI, international, and Solta Medical, with a strong pipeline and operational consistency. XIFAXAN’s exclusivity is under legal review, with key trial data expected early next year. Capital structure flexibility and innovation remain top priorities.
Bausch Health's Aesthetics Business, Solta Medical, Acquires Longtime Distribution Partner, the Shibo Group, to Strengthen Presence in China
Transaction boosts Solta Medical's position to meet rising demand in China's growing aesthetics market LAVAL, QC / ACCESS Newswire / December 1, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC)...
Bausch Health Announces Launch of Offers to Exchange Certain Existing Senior Secured Notes
LAVAL, QC / ACCESS Newswire / November 24, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced the commencement of offers to exchange the Company...
Bausch Health to Participate in the 8th Annual Evercore Healthcare Conference
LAVAL, QC / ACCESS Newswire / November 18, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that Jean-Jacques Charhon, Executive Vice President and Chief Financial Officer, wil...
Bausch + Lomb CEO Brent Saunders on growth outlook: Biggest contributor will be in surgical
Bausch + Lomb CEO Brent Saunders joins 'Squawk Box' to preview the company's investor day, details of the company's three-year plan for profitable growth, impact of tariffs, and more.
Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will outline the next chapter ...